Want to see HK:2269 full AI Analyst Report?
Wuxi Biologics (Cayman) (2269) Financial Statements
Wuxi Biologics (Cayman) Financial Overview
Wuxi Biologics (Cayman)'s market cap is currently $183.11B. The company's EPS TTM is $1.21; its P/E ratio is 31.13; Wuxi Biologics (Cayman) is estimated to report earnings on March 23, 2027, and the estimated EPS forecast is $0.85. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 21.79B | $ 18.68B | $ 17.03B | $ 15.27B | $ 10.29B |
| Gross Profit | $ 10.02B | $ 7.65B | $ 6.83B | $ 6.72B | $ 4.83B |
| Operating Income | $ 6.64B | $ 4.97B | $ 4.45B | $ 4.34B | $ 3.19B |
| EBITDA | $ 8.37B | $ 6.43B | $ 5.50B | $ 6.22B | $ 4.51B |
| Net Income | $ 4.91B | $ 3.36B | $ 3.40B | $ 4.42B | $ 3.39B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 15.74B | $ 10.71B | $ 11.24B | $ 8.71B | $ 11.13B |
| Total Assets | $ 63.72B | $ 56.98B | $ 56.58B | $ 49.56B | $ 44.03B |
| Total Debt | $ 3.11B | $ 4.94B | $ 4.56B | $ 4.42B | $ 4.30B |
| Net Debt | $ -6.12B | $ -3.34B | $ -5.11B | $ -1.97B | $ -4.71B |
| Total Liabilities | $ 10.66B | $ 11.50B | $ 12.56B | $ 13.35B | $ 11.33B |
| Stockholders' Equity | $ 47.27B | $ 41.82B | $ 40.33B | $ 35.05B | $ 32.28B |
| Cash Flow | |||||
| Free Cash Flow | $ 2.80B | $ 1.29B | $ 437.20M | $ -326.72M | $ -3.09B |
| Operating Cash Flow | $ 6.39B | $ 5.22B | $ 4.67B | $ 5.54B | $ 3.43B |
| Investing Cash Flow | $ -3.38B | $ -3.94B | $ -3.23B | $ -5.91B | $ -9.60B |
| Financing Cash Flow | $ -1.95B | $ -2.75B | $ 1.96B | $ -2.59B | $ 8.21B |
Currency in CNY
